Protease inhibitor therapy for hepatitis C virus-infection

@article{deLeuw2018ProteaseIT,
  title={Protease inhibitor therapy for hepatitis C virus-infection},
  author={Philipp de Leuw and Christoph Stephan},
  journal={Expert Opinion on Pharmacotherapy},
  year={2018},
  volume={19},
  pages={577 - 587}
}
ABSTRACT Introduction: The hepatitis C virus (HCV) has affected an estimated of 80 million individuals worldwide and is a strain on public health. Around 25–30% of patients in Europe and the US who are infected with HIV are coinfected with HCV. Prior to 2013, treatment modalities containing an NS3/4A protease inhibitor in combination with pegylated interferon and ribavirin improved sustained virological response (SVR) rates. However, rates of severe side effects were high. Nowadays, oral direct… 
View on Taylor & Francis
ncbi.nlm.nih.gov
40 Citations
Highly Influential Citations
1
Background Citations
8

40 Citations

Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients

Investigation in a DAA treatment naïve cohort of Uruguayan patients infected with chronic hepatitis C found that naturally occurring substitutions conferring resistance to NS5A and NS5B inhibitors were present in 8% and 19.2%, respectively, of treatment-naïve HCV genotype 1 infected patients.

The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection

The role of interferon-α decreased dramatically and, in late 2017, IFN-α was no longer recommended by professional societies as a first-line treatment for any HCV genotype or patient population, marking the end of the IFn-α era.

Resistance mutations of NS3 and NS5b in treatment-naïve patients infected with hepatitis C virus in Santa Catarina and Rio Grande do Sul states, Brazil

It is shown that mutations in NS3 and NS5b genes are present in Brazilian isolates from therapy-naïve HCV patients, as well as naturally occurring resistance mutations in HCV NS2 and NS3 regions in treatment-naive patients.

Towards curative therapy of chronic viral hepatitis.

The current status of therapy development for chronic viral hepatitis that ultimately aims at cure is summarized, with a major step forward has been the development of curative antiviral therapy for chronic hepatitis C.

Hepatitis C Virus: 30 Years after Its Discovery.

  • M. Houghton
  • Biology, Medicine
    Cold Spring Harbor perspectives in medicine
  • 2019
Evidence for the existence of another hepatitis-causing pathogen, other than the known hepatitis A and B viruses, emerged in the mid-1970s and led to the development of effective direct-acting antivirals targeting its serine protease, polymerase, and nonstructural protein 5A that resulted in the approval of orally available drug combinations.

Signature of natural resistance in NS3 protease revealed by deep sequencing of HCV strains circulating in Iran.

  • L. CuypersM. Thijssen M. Pourkarim
  • Medicine, Biology
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • 2019

Alphavirus-based hepatitis C virus therapeutic vaccines: can universal helper epitopes enhance HCV-specific cytotoxic T lymphocyte responses?

It is hypothesized that the additional effect of the sigHELP-KDEL cassette in SFV-based vaccines depends on the immunogenicity, nature, and stability of the target antigen expressed by the vaccine.

Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors.

Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.

In silico and in vitro study of peptidomimetic protease inhibitors against Zika and Tick-Borne Encephalitis Virus

In silico molecular dynamics techniques, additional compounds were designed and tested in an in vitro enzymatic assay against the Zika NS2B/NS3 protease to better understand the mechanism of action of these inhibitors, and paves the way for the further development of a more potent drug-like compound, and eventually a possible pan-Flavivirus protease inhibitor.

References

SHOWING 1-10 OF 104 REFERENCES

Grazoprevir/elbasvir fixed-dose combination for hepatitis C.

The pharmacokinetics, clinical efficacy and safety profile pertaining to grazoprevir/elbasvir fixed-dose combination for CHC is reviewed.

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients

B baseline resistance testing allows the selection of at least one RAVs-free treatment option for nearly all patients enabling a potentially cost- and efficacy-optimized treatment of chronic hepatitis C.

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.

Expert opinion on the treatment of patients with chronic hepatitis C

Potential approaches for the optimization of treatment for patients with HCV genotype 1 are explored, considering shorter treatment periods for Patients with a rapid virological response (RVR), increasing treatment period for slow responders, and increasing RBV dose are all suggestions.

MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

The preclinical profile of MK-5172 is reported, a novel P2-P4 quinoxaline macrocyclic NS3/4a protease inhibitor currently in clinical development that is anticipated to be broadly active against multiple HCV genotypes and clinically important resistance variants and highly suited for incorporation into newer all-oral regimens.

HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study

HIV-coinfection is associated with worse response to DAA-based therapy against HCV infection, and in patients receiving IFN-free therapy, this fact seems to be mainly driven by a higher rate of relapses among HIV- coinfected subjects.

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.

Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.

Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System

Hepatitis B virus reactivation may occur spontaneously, it is more frequent in patients with immunodeficiency due to HIV, autoimmune disease, or organ transplantation, or it may be triggered by initiation of immunosuppressive therapy.

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?

The identification of predictive factors for a response to treatment, and the occurrence of SAE, have enabled us to establish limits for the use of this anti-HCV therapy in the transplant setting.
...